Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine for TAP block in bariatric surgery
NCT05537883Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of liposomal bupivacaine in postoperative pain, sponsored by Wake Forest University Health Sciences. Primary endpoint: Visual Analogue Scale at 24 hours. Started Nov 2022; status: completed.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05537883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537883.